Accelerate your biologic drug development with Praesto®
Praesto Jetted A50 to be used in monoclonal antibody treatment.
Purolite Ltd., Cardiff, South Wales - Purolite Ltd., a leading manufacturer of resin-based separation, purification and extraction technologies, today announces that Praesto® Jetted A50, an agarose-based Protein A chromatography resin, has been incorporated into the commercial manufacturing process of an FDA-approved monoclonal antibody treatment by one of the world’s leading contract manufacturing organizations.
Praesto resins are an integral technology used by biopharmaceutical developers for the purification of modern medicines for the treatment of cancer, rheumatoid arthritis, dementia and diabetes. Praesto Jetted A50, launched in April 2018, is Purolite’s ‘best-in-class’ Protein A chromatography resin, utilizing a patented, ‘Jetting’ manufacturing technology for uniform resin beads, a highly desirable characteristic for chromatographic applications.